It is not a drug, dietary supplement, or product intended for human or animal consumption.
Nausea at this dose level is moderate in about 30-40% of users
Gastroesophageal reflux disease (GERD): Delayed gastric emptying caused by GLP-1 medications can exacerbate reflux symptoms
The medication works at the same rate regardless of whether you inject on day six or day seven of your cycle
Other options are also in development
This coordinated engagement across the pancreas, brain, gut, liver, and adipose tissue underlies the mechanistic rationale for dual GLP-1/GIP receptor agonists, and explains why they have been described as super GLP-1RAs, reflecting genuine potentiation of GLP-1 action by GIP receptor agonist co-activation